Zobrazeno 1 - 10
of 314
pro vyhledávání: '"Graux, C."'
Autor:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y, Ossenkoppele, G J
Publikováno v:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ossenkoppele, G.J., Breems, D.A., Stuessi, G., Norden, Y. van, Bargetzi, M., Biemond, B.J., Borne, P.A. von dem, Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J.J.J.W., Jaspers, A., Jongen-Lavrencic, M., Jongh, E. de, Klein, S.K., Klift, M. van der, Kooy, M.V., Maertens, J., Micheaux, L., Poel, M.W.M. van der, Rhenen, A. van, Tick, L., Valk, P., Vekemans, M.C., Velden, W.J.F.M. van der, Weerdt, O. de, Pabst, T., Manz, M., Lowenberg, B., Havelange, Moors, I., Obberg, F. van, Maertens, J.A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Gjertsen, B.T., Passweg, J., Heim, D., Giovanni, S., Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M.G., Loosdrecht, A. van de, Janssen, J.J.W.M., Esser, J.W.J. van, Brouwer, R.E., Lammeren-Venema, D. van, Levin, M.D., Tick, L.W., Legdeur, M.C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J.H., Schouten, H.C., Cornelissen, J., Wouters, B., Raaijmakers, H.G.M., Kuball, J., Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK
Publikováno v:
Leukemia, 1751-1759. Nature Publishing Group
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
Contains fulltext : 225470.pdf (Publisher’s version ) (Closed access) More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lowenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B.J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L.W., Jongen-Lavrencic, M., Kooy, M.V., Vekemans, M.C., Velden, W.J.F.M. van der, Beverloo, B., Michaux, L., Graux, C., Deeren, D., Weerdt, O. de, Esser, J.W.J. van, Bargetzi, M., Klein, S.K., Gadisseur, A., Westerweel, P.E., Veelken, H., Gregor, M., Silzle, T., Lammeren-Venema, D. van, Moors, I., Breems, D.A., Hoogendoorn, M., Legdeur, M.C.J.C., Fischer, T., Kuball, J., Cornelissen, J., Porkka, K., Juliusson, G., Meyer, P., Hoglund, M., Gjertsen, B.T., Janssen, J.J.W.M., Huls, G., Passweg, J., Cloos, J., Valk, P.J.M., Elssen, C.H.M.J. van, Manz, M.G., Floisand, Y., Ossenkoppele, G.J., Dutch-Belgian Hemato-Oncology Coop, Swiss Grp Clinical Canc Res SAKK
Publikováno v:
Blood Adv
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121
Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly
Autor:
Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J.
Publikováno v:
Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4231d8d48f8da424335ae95804aeb6bc
https://research.vumc.nl/en/publications/05f113e6-d597-4250-99cf-855010361d8a
https://research.vumc.nl/en/publications/05f113e6-d597-4250-99cf-855010361d8a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, Oliver
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b255920b78c8f42dc4e92fc9813e17ff
https://orca.cardiff.ac.uk/id/eprint/103058/1/leu2017159a.pdf
https://orca.cardiff.ac.uk/id/eprint/103058/1/leu2017159a.pdf